Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 5/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329484 | 0.91 | CSNK1D (0.41) | CSNK1ECSNK1DDHODHPOLB | |
| SCHEMBL1762881 | 0.90 | CSNK1D (0.41) | CSNK1ECSNK1DDHODHMAPTTP53 | |
| SCHEMBL1762911 | 0.89 | POLB (0.36) | CSNK1ECSNK1DDHODHSCN9APOLB | |
| SCHEMBL29198567 | 0.86 | DHODH (0.39) | CSNK1ECSNK1DDHODH | |
| SCHEMBL18691186 | 0.85 | POLB (0.35) | CSNK1ECSNK1DDHODHSCN9APOLB | |
| SCHEMBL19436813 | 0.85 | CSNK1E (0.38) | CSNK1ECSNK1DDHODH | |
| SCHEMBL30132994 | 0.85 | CSNK1E (0.38) | CSNK1ECSNK1DDHODH | |
| SCHEMBL1763152 | 0.84 | CSNK1E (0.43) | CSNK1ECSNK1DPOLB | |
| SCHEMBL28483197 | 0.84 | DHODH (0.36) | CSNK1ECSNK1DDHODH | |
| SCHEMBL1762883 | 0.84 | POLB (0.38) | CSNK1ECSNK1DDHODHPOLBPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263327-B2 | Enzymatic method for the production of microcapsules | BASF SE (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20110124590-A1 | Oil-in-Water Emulsion Comprising Solvent, Water, Surfactant and Pesticide | BASF SE (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20100120617-A1 | Enzymatic Method for the Production of Microcapsules | BASF SE | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120617-A1 | Enzymatic Method for the Production of Microcapsules | MGAM, ACHE, BCHE | CSNK1E 1043/4885CSNK1D 1071/4885DHODH 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.